日本語 
Pahr Therapeutics has raised $14 million in seed funding. This money will help develop new treatments for pulmonary arterial hypertension (PAH). PAH is a serious and progressive cardiovascular condition. RA Capital Management, AN Venture Partners, and UTEC led the funding round. The funds will help the company create new therapies for PAH. This is based on recent scientific discoveries. This area has few treatment options and a big unmet clinical need.
RA Capital’s incubator, Raven, gave rise to Pahr Therapeutics, which Neil Buckley leads. The company’s science comes from research at Japan’s National Cerebral and Cardiovascular Center. Co-founder Dr. Yoshikazu Nakaoka has done a lot of work on the molecular causes of PAH. This research underpins Pahr Therapeutics’s innovative therapeutic strategy.
Also Read: Alloy Therapeutics, KSAC team up to grow Japan Biotechs
The new board appointments by lead investors show solid support. They also provide smart guidance as the company moves forward. The funding indicates a growing interest among investors in early-stage biotech companies. These companies target rare and complex diseases. They focus primarily on cardiovascular and pulmonary medicine.
English